The anti-metastatic effects of the phytoestrogen arctigenin on human breast cancer cell lines regardless of the status of ER expression

International Journal of Oncology

Volumn 50, Issue 2, 2017, Pages 727-735

  Maxwell, Thressi ^a   Chun, So Young ^a   Lee, Kyu Shik ^a   Kim, Soyoung ^a   Nam, Kyung Soo ^a  

^a Dongguk University College of Medicine   (South Korea)

Author keywords

Arctigenin; Estrogen receptor; MCF 7 and MDA MB 231 human breast cancer cells; Metastasis; Phytoestrogen

Indexed keywords

ARCTIGENIN; ESTROGEN RECEPTOR; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE 1; UROKINASE; FURAN DERIVATIVE; LIGNAN; MMP9 PROTEIN, HUMAN; PHYTOESTROGEN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL INVASION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MCF-7 CELL LINE; MDA-MB-231 CELL LINE; METASTASIS INHIBITION; MIGRATION INHIBITION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ZYMOGRAPHY; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; FURANS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGNANS; MATRIX METALLOPROTEINASE 9; MCF-7 CELLS; NEOPLASM METASTASIS; PHYTOESTROGENS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 85013040741     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3825     Document Type: Article

References (41)

1. Gao H, Li G, Zhang J and Zeng J: Arctigenin: A lignan from Arctium lappa. Acta Crystallogr Sect E Struct Rep Online 64: o1538, 2008.
2. Kim Y, Hollenbaugh JA, Kim DH and Kim B: Novel PI3K/Akt inhibitors screened by the cytoprotective function of human immunodeficiency virus type 1 Tat. PLoS One 6: e21781, 2011.
3. Hayashi K, Narutaki K, Nagaoka Y, Hayashi T and Uesato S: Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus. Biol Pharm Bull 33: 1199-1205, 2010.
4. Swarup V, Ghosh J, Mishra MK and Basu A: Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan. J Antimicrob Chemother 61: 679-688, 2008.
5. Lee JY and Kim CJ: Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits type I-IV allergic inflammation and pro-inflammatory enzymes. Arch Pharm Res 33: 947-957, 2010.
6. Kang HS, Lee JY and Kim CJ: Anti-inflammatory activity of arctigenin from Forsythiae Fructus. J Ethnopharmacol 116: 305-312, 2008.
7. Yao X, Li G, Lü C, Xu H and Yin Z: Arctigenin promotes degradation of inducible nitric oxide synthase through CHIPassociated proteasome pathway and suppresses its enzyme activity. Int Immunopharmacol 14: 138-144, 2012.
8. Tsai WJ, Chang CT, Wang GJ, Lee TH, Chang SF, Lu SC and Kuo YC: Arctigenin from Arctium lappa inhibits interleukin-2 and interferon gene expression in primary human T lymphocytes. Chin Med 6: 12, 2011.
9. Cho MK, Park JW, Jang YP, Kim YC and Kim SG: Potent inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by dibenzylbutyrolactone lignans through inhibition of I-kappaBalpha phosphorylation and of p65 nuclear translocation in macrophages. Int Immunopharmacol 2: 105-116, 2002.
10. Cho MK, Jang YP, Kim YC and Kim SG: Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: The role in TNF-alpha inhibition. Int Immunopharmacol 4: 1419-1429, 2004.
11. Jeong JB, Hong SC, Jeong HJ and Koo JS: Arctigenin induces cell cycle arrest by blocking the phosphorylation of Rb via the modulation of cell cycle regulatory proteins in human gastric cancer cells. Int Immunopharmacol 11: 1573-1577, 2011.
12. Susanti S, Iwasaki H, Itokazu Y, Nago M, Taira N, Saitoh S and Oku H: Tumor specific cytotoxicity of arctigenin isolated from herbal plant Arctium lappa L. J Nat Med 66: 614-621, 2012.
13. Awale S, Lu J, Kalauni SK, Kurashima Y, Tezuka Y, Kadota S and Esumi H: Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res 66: 1751-1757, 2006.
14. Kim JY, Hwang JH, Cha MR, Yoon MY, Son ES, Tomida A, Ko B, Song SW, Shin-ya K, Hwang YI, et al: Arctigenin blocks the unfolded protein response and shows therapeutic antitumor activity. J Cell Physiol 224: 33-40, 2010.
15. Zhang S, Li J, Song S, Li J, Tong R, Zang Z, Jiang Q and Cai L : Integrated in silico and experimental methods revealed that Arctigenin inhibited angiogenesis and HCT116 cell migration and invasion through regulating the H1F4A and Wnt/β-catenin pathway. Mol Biosyst 11: 2878-2884, 2015.
16. Hausott B, Greger H and Marian B: Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. J Cancer Res Clin Oncol 129: 569-576, 2003.
17. Gu Y, Scheuer C, Feng D, Menger MD and Laschke MW: Inhibition of angiogenesis: A novel antitumor mechanism of the herbal compound arctigenin. Anticancer Drugs 24: 781-791, 2013.
18. Gu Y, Qi C, Sun X, Ma X, Zhang H, Hu L, Yuan J and Yu Q: Arctigenin preferentially induces tumor cell death under glucose deprivation by inhibiting cellular energy metabolism. Biochem Pharmacol 84: 468-476, 2012.
19. Susanti S, Iwasaki H, Inafuku M, Taira N and Oku H: Mechanism of arctigenin-mediated specific cytotoxicity against human lung adenocarcinoma cell lines. Phytomedicine 21: 39-46, 2013.
20. Yang S, Ma J, Xiao J, Lv X, Li X, Yang H, Liu Y, Feng S and Zhang Y: Arctigenin anti-tumor activity in bladder cancer T24 cell line through induction of cell-cycle arrest and apoptosis. Anat Rec (Hoboken) 295: 1260-1266, 2012.
21. Huang K, Li LA, Meng YG, You YQ, Fu XY and Song L: Arctigenin promotes apoptosis in ovarian cancer cells via the iNOS/NO/STAT3/survivin signalling. Basic Clin Pharmacol Toxicol 115: 507-511, 2014.
22. Hsieh CJ, Kuo PL, Hsu YC, Huang YF, Tsai EM and Hsu YL: Arctigenin, a dietary phytoestrogen, induces apoptosis of estrogen receptor-negative breast cancer cells through the ROS/p38 MAPK pathway and epigenetic regulation. Free Radic Biol Med 67: 159-170, 2014.
23. Jin JS, Lee JH and Hattori M: Ligand binding affinities of arctigenin and its demethylated metabolites to estrogen receptor alpha. Molecules 18: 1122-1127, 2013.
24. Matsumura A, Ghosh A, Pope GS and Darbre PD: Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 94: 431-443, 2005.
25. Rice S and Whitehead SA: Phytoestrogens and breast cancer-promoters or protectors? Endocr Relat Cancer 13: 995-1015, 2006.
26. Lephart ED: Modulation of aromatase by phytoestrogens. Enzyme Res 2015: 594656, 2015. doi: 10.1155/2015/594656
27. Whitehead SA and Lacey M: Phytoestrogens inhibit aromatase but not 17beta-hydroxysteroid dehydrogenase (HSD) type 1 in human granulosa-luteal cells: Evidence for FSH induction of 17beta-HSD. Hum Reprod 18: 487-494, 2003.
28. Low YL, Taylor JI, Grace PB, Dowsett M, Scollen S, Dunning AM, Mulligan AA, Welch AA, Luben RN, Khaw KT, et al: Phytoestrogen exposure correlation with plasma estradiol in postmenopausal women in European Prospective Investigation of Cancer and Nutrition-Norfolk may involve diet-gene interactions. Cancer Epidemiol Biomarkers Prev 14: 213-220, 2005.
29. DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin 64: 52-62, 2014.
30. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG and Lee JS: Cancer statistics in Korea: Incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 45: 1-14, 2013.
31. Straatman K: Wound healing assay. University of Leicester, College of Medicine, Biological Sciences and Psychology, Advanced Imaging Facilities, 2008.
32. Loughlin DT and Artlett CM: Modification of collagen by 3-deoxyglucosone alters wound healing through differential regulation of p38 MAP kinase. PLoS One 6: e18676, 2011.
33. Lee K, Shin J, Kwon Y, Moon D and Nam K: Suppression of cancer progression and metastasis in HT-29 human colorectal adenocarcinomas by deep sea water. Biotechnol Bioprocess Eng 18: 194-200, 2013.
34. Mehner C, Hockla A, Miller E, Ran S, Radisky DC and Radisky ESR: Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basallike triple negative breast cancer. Oncotarget 5: 2736-2749, 2014.
35. Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V and Brünner N: Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14: 297-307, 1996.
36. Lungu G, Covaleda L, Mendes O, Martini-Stoica H and Stoica G: FGF-1-induced matrix metalloproteinase-9 expression in breast cancer cells is mediated by increased activities of NF-kappaB and activating protein-1. Mol Carcinog 47: 424-435, 2008.
37. Moritani S, Nomura M, Takeda Y and Miyamoto K: Cytotoxic components of bardanae fructus (goboshi). Biol Pharm Bull 19: 1515-1517, 1996.
38. McCawley LJ and Matrisian LM: Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today 6: 149-156, 2000.
39. Duffy MJ: The urokinase plasminogen activator system: Role in malignancy. Curr Pharm Des 10: 39-49, 2004.
40. Cheepala SB, Yin W, Syed Z, Gill JN, McMillian A, Kleiner HE, Lynch M, Loganantharaj R, Trutschl M, Cvek U, et al: Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer 8: 27, 2009.
41. Lilleholt LL, Johansen C, Arthur JS, Funding A, Bibby BM, Kragballe K and Iversen L: Role of p38 mitogen-activated protein kinase isoforms in murine skin inflammation induced by 12-O-tetradecanoylphorbol 13-acetate. Acta Derm Venereol 91: 271-278, 2011.